NRG Therapeutics appoints Paul Thompson as CDO
NRG Therapeutics has expanded its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).
In his role at NRG, Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.
NRG5051 is an oral, CNS-penetrant small molecule inhibitor of the mitochondrial permeability transition pore (mPTP) acting via a novel mechanism of action (MoA).
Inhibition of the mPTP has been shown to be profoundly neuroprotective and significantly reduces neuroinflammation in pre-clinical models of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), and Parkinson’s. Thompson will also take responsibility for all non-clinical development functions within NRG.
Thompson has over 25 years’ experience in translational research, early clinical development, and pharma R&D, with a focus predominantly on neurology. Most recently he was CSO at Mission Therapeutics for five years, responsible for delivery of clinical candidate USP30 inhibitors for renal and CNS disorders.
Thompson led the MTX325 USP30 inhibitor project into Phase I for Parkinson’s, part funded by the Michael J Fox Foundation and co-authored two manuscripts on mitochondrial dysfunction and Parkinson’s in Nature journals.
Thompson said: “Developing new drugs to treat neurological diseases is very challenging but I have been very encouraged by the compelling in vivo efficacy data for NRG5051 in rodent models of Parkinson’s and ALS/MND, that has validated the molecules’ novel MoA and demonstrated the therapeutic potential of NRG5051.”
Diana Turner, Deputy Editor, DDW
